Clinical Exome Sequencing (CES) + Mitochondrial Genome Sequencing – ONCO

Overview

Clinical Exome Sequencing (CES) + Mitochondrial Genome Sequencing – ONCO is an advanced genetic test designed to identify inherited and acquired genetic variations associated with cancer. It analyzes thousands of clinically relevant genes in the exome along with the complete mitochondrial genome to provide comprehensive insights into cancer risk, diagnosis, prognosis, and personalized treatment options.

Why is this Test Important?

• Detects cancer-associated genetic mutations.
• Identifies hereditary cancer syndromes.
• Supports precision oncology and targeted therapies.
• Assists in prognosis and treatment planning.
• Evaluates mitochondrial DNA variations linked to cancer development.

Who Should Consider This Test?

• Individuals with a personal or family history of cancer.
• Patients with early-onset or rare cancers.
• Individuals with multiple primary tumors.
• Patients requiring targeted therapy selection.
• Cases with unexplained hereditary cancer risk.

Sample Required

• Peripheral Blood / DNA Sample

Benefits

✔ Comprehensive analysis of clinically significant genes
✔ Complete mitochondrial genome assessment
✔ Supports personalized cancer management
✔ Helps identify hereditary cancer predisposition
✔ Facilitates informed clinical decision-making

When is the Test Recommended?

• Suspected hereditary cancer syndromes
• Precision oncology evaluations
• Family cancer risk assessment
• Complex or undiagnosed cancer cases
• Selection of targeted treatment strategies

Advanced BioCare Laboratories

Accurate genetic testing solutions for comprehensive cancer risk assessment and personalized healthcare.

#ClinicalExomeSequencing #MitochondrialGenomeSequencing #OncologyTesting #CancerGenetics #PrecisionMedicine #GeneticTesting #HereditaryCancer #CancerScreening #AdvancedBioCare #Dermafact #gynofact